Camille Amadieu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Camille Amadieu has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
Audrey M. Neyrinck
Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, UCLouvain, Brussels, Belgium
5 shared publications- Nathalie M. Delzenne
UCLouvain, Louvain Drug Research Institute, LDRI, Metabolism and Nutrition Research Group, MNut, Brussels, Belgium
4 shared publications - Sophie Layé
Université de Bordeaux, INRAE, Bordeaux INP, NutriNeuro, 146 rue Léo Saignat, 33076 Bordeaux, France
4 shared publications - Agnès Nadjar
INRA, Nutrition et Neurobiologie Intégrée, UMR 1286, 33076 Bordeaux, France; Université de Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France
3 shared publications - Corinne Joffre
Université de Bordeaux, INRAE, Bordeaux INP, NutriNeuro, UMR1286, Bordeaux, France
3 shared publications Giorgia Zamariola
Research Institute for Psychological Sciences, UCLouvain, Louvain-La-Neuve, Belgium
3 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Springer Nature in Translational Psychiatry
Translational evidence of tricarboxylic acid cycle disruptions in obesity: relevance to neuropsychiatric symptoms
Obesity is a major public health concern frequently associated with an increased susceptibility to neuropsychiatric symptoms, highlighting the need to elucidate the pathophysiological mechanisms underlying this comorbidity. While converging evidence supports a role for chronic low-grade inflammation, emerging data suggest that additional immunometabolic alterations may also participate, particularly disruptions in mitochondrial tricarboxylic acid (TCA) cycle activity, a central component of cellular energy production. This translational study investigated whether TCA cycle alterations are associated with obesity-related neuropsychiatric symptoms, and whether their associations differ across symptom dimensions. Plasma levels of TCA cycle metabolites were assessed in 83 adults with obesity (BMI > 30 kg/m²), along with depressive (Montgomery-Asberg Depression Rating Scale, MADRS), anxiety (State-Trait Anxiety Inventory, STAI-state form), and fatigue symptoms (Multidimensional Fatigue Inventory, MFI). Concurrently, depressive-like (Sucrose Preference Test, Forced Swim Test) and anxiety-like behaviors (Elevated Plus-Maze) were measured in C57BL/6J male mice chronically exposed to high-fat diet (HFD), together with plasma and brain (striatum, hippocampus, frontal cortex) TCA cycle metabolite levels. Lower circulating metabolite levels were associated with more severe neuropsychiatric symptoms in obese participants, particularly fatigue and reduced motivation. In addition, the preclinical study identified region-specific associations between brain TCA cycle metabolite levels and behavioral outcomes, which may be modulated by HFD exposure. By providing novel evidence linking TCA cycle dysregulation and neuropsychiatric comorbidities in obesity, these findings highlight metabolites of potential interest and suggest that mitochondrial immunometabolic alterations may contribute to obesity-related neuropsychiatric symptoms.
- 1 October 2026
- Published by Springer Nature in Translational Psychiatry
Open AccessTranslational evidence of tricarboxylic acid cycle disruptions in obesity: relevance to neuropsychiatric symptoms
Obesity is a major public health concern frequently associated with an increased susceptibility to neuropsychiatric symptoms, highlighting the need to elucidate the pathophysiological mechanisms underlying this comorbidity. While converging evidence supports a role for chronic low-grade inflammation, emerging data suggest that additional immunometabolic alterations may also participate, particularly disruptions in mitochondrial tricarboxylic acid (TCA) cycle activity, a central component of cellular energy production. This translational study investigated whether TCA cycle alterations are associated with obesity-related neuropsychiatric symptoms, and whether their associations differ across symptom dimensions. Plasma levels of TCA cycle metabolites were assessed in 83 adults with obesity (BMI > 30 kg/m²), along with depressive (Montgomery-Asberg Depression Rating Scale, MADRS), anxiety (State-Trait Anxiety Inventory, STAI-state form), and fatigue symptoms (Multidimensional Fatigue Inventory, MFI). Concurrently, depressive-like (Sucrose Preference Test, Forced Swim Test) and anxiety-like behaviors (Elevated Plus-Maze) were measured in C57BL/6J male mice chronically exposed to high-fat diet (HFD), together with plasma and brain (striatum, hippocampus, frontal cortex) TCA cycle metabolite levels. Lower circulating metabolite levels were associated with more severe neuropsychiatric symptoms in obese participants, particularly fatigue and reduced motivation. In addition, the preclinical study identified region-specific associations between brain TCA cycle metabolite levels and behavioral outcomes, which may be modulated by HFD exposure. By providing novel evidence linking TCA cycle dysregulation and neuropsychiatric comorbidities in obesity, these findings highlight metabolites of potential interest and suggest that mitochondrial immunometabolic alterations may contribute to obesity-related neuropsychiatric symptoms.
- Open Access
- 3 October 2025
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 122 (6) , 1625-1635
Effect of saffron extract supplementation on mood in healthy adults with subclinical symptoms of depression: a randomized, double-blind placebo-controlled study
- 3 October 2025
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 122 (6) , 1625-1635
Open AccessEffect of saffron extract supplementation on mood in healthy adults with subclinical symptoms of depression: a randomized, double-blind placebo-controlled study
- Open Access
- 13 May 2025
- Published by Wiley in Liver International
- Vol. 45 (6) , e70128
Serum Metabolite Profile in Progressive Versus Nonprogressive Alcohol‐Related Liver Disease: A Cross‐Sectional Metabolomics Study
Background and Aims: Alcohol‐related liver disease (ALD) is a major cause of mortality and disability‐adjusted life years. It is not fully understood why a small proportion of patients develop progressive forms of ALD (e.g., fibrosis and cirrhosis). Differences in the metabolic processes could be behind the individual progression of ALD. Our aim was to examine differences in serum metabolome between patients with nonprogressive ALD and patients with an early form of progressive ALD.Methods: The study had three study groups: progressive ALD (alcohol‐related steatohepatitis or early‐stage fibrosis, n = 50), nonprogressive ALD (simple steatosis, n = 50) and healthy controls (n = 32). Both ALD groups took part in a voluntary alcohol rehabilitation programme. A nontargeted metabolomics analysis and targeted analysis of short‐chain fatty acids were done to the serum samples taken on the day of admission.Results: We found 111 significantly (p < 0.0005) altered identified metabolites between the study groups. Our main finding was that levels of glycine‐conjugated bile acids (Cohen's d = 0.90–0.91), glutamic acid (d = 1.01), 7‐methylguanine (d = 0.77) and several phosphatidylcholines (d = 0.61–0.85) were elevated in the progressive ALD group in comparison to the nonprogressive ALD group. Glycine‐conjugated bile acids, glutamic acid and 7‐methylguanine also positively correlated with increased levels of aspartate aminotransferase, alanine aminotransferase, gamma‐glutamyl transferase, cell death biomarker M65 and liver stiffness.Conclusions: Our results indicate that the enterohepatic cycle of glycine‐conjugated bile acids, as well as lipid and energy metabolism, is altered in early forms of progressive ALD. These metabolic processes could be a target for preventing the progression of ALD.
- 13 May 2025
- Published by Wiley in Liver International
- Vol. 45 (6) , e70128
Open AccessSerum Metabolite Profile in Progressive Versus Nonprogressive Alcohol‐Related Liver Disease: A Cross‐Sectional Metabolomics Study
Background and Aims: Alcohol‐related liver disease (ALD) is a major cause of mortality and disability‐adjusted life years. It is not fully understood why a small proportion of patients develop progressive forms of ALD (e.g., fibrosis and cirrhosis). Differences in the metabolic processes could be behind the individual progression of ALD. Our aim was to examine differences in serum metabolome between patients with nonprogressive ALD and patients with an early form of progressive ALD.Methods: The study had three study groups: progressive ALD (alcohol‐related steatohepatitis or early‐stage fibrosis, n = 50), nonprogressive ALD (simple steatosis, n = 50) and healthy controls (n = 32). Both ALD groups took part in a voluntary alcohol rehabilitation programme. A nontargeted metabolomics analysis and targeted analysis of short‐chain fatty acids were done to the serum samples taken on the day of admission.Results: We found 111 significantly (p < 0.0005) altered identified metabolites between the study groups. Our main finding was that levels of glycine‐conjugated bile acids (Cohen's d = 0.90–0.91), glutamic acid (d = 1.01), 7‐methylguanine (d = 0.77) and several phosphatidylcholines (d = 0.61–0.85) were elevated in the progressive ALD group in comparison to the nonprogressive ALD group. Glycine‐conjugated bile acids, glutamic acid and 7‐methylguanine also positively correlated with increased levels of aspartate aminotransferase, alanine aminotransferase, gamma‐glutamyl transferase, cell death biomarker M65 and liver stiffness.Conclusions: Our results indicate that the enterohepatic cycle of glycine‐conjugated bile acids, as well as lipid and energy metabolism, is altered in early forms of progressive ALD. These metabolic processes could be a target for preventing the progression of ALD.
- Open Access
Differences in the serum metabolomic profile of progressive alcohol-related liver disease in comparison to non-progressive alcohol-related liver disease: a cross sectional metabolomics study
Alcohol-related liver disease (ALD) is a major cause of mortality and disability adjusted life years. It is not fully understood why a small proportion of patients develop progressive forms of ALD (e.g. fibrosis, cirrhosis). Differences in the metabolic processes could be behind the individual progression of ALD. Our aim was to examine differences in serum metabolome between patients with non-progressive ALD and patients with an early form of progressive ALD. The study had three study groups: progressive ALD (alcohol-related steatohepatitis or early-stage fibrosis, n=50), non-progressive ALD (simple steatosis, n=50) and healthy controls (n=32). Both ALD groups took part in a voluntary alcohol rehabilitation program. A non-targeted metabolomics analysis and targeted analysis of short chain fatty acids was done to the serum samples taken on the day of admission. We found 111 significantly (p<0.0005) altered identified metabolites between the study groups. Our main finding was that levels of glycine conjugated bile acids, glutamic acid, 7-methylguanine and several phosphatidylcholines were elevated in the progressive ALD group in comparison to both the non-progressive ALD group and the controls. Glycine conjugated bile acid, glutamic acid and 7-methylguanine also positively correlated with increased levels of aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, cell death biomarker M65, and liver stiffness. Our results indicate that the enterohepatic cycle of glycine conjugated bile acids as well as lipid and energy metabolism are altered in early forms of progressive ALD. These metabolic processes could be a target for preventing progression of ALD.
Open AccessDifferences in the serum metabolomic profile of progressive alcohol-related liver disease in comparison to non-progressive alcohol-related liver disease: a cross sectional metabolomics study
Alcohol-related liver disease (ALD) is a major cause of mortality and disability adjusted life years. It is not fully understood why a small proportion of patients develop progressive forms of ALD (e.g. fibrosis, cirrhosis). Differences in the metabolic processes could be behind the individual progression of ALD. Our aim was to examine differences in serum metabolome between patients with non-progressive ALD and patients with an early form of progressive ALD. The study had three study groups: progressive ALD (alcohol-related steatohepatitis or early-stage fibrosis, n=50), non-progressive ALD (simple steatosis, n=50) and healthy controls (n=32). Both ALD groups took part in a voluntary alcohol rehabilitation program. A non-targeted metabolomics analysis and targeted analysis of short chain fatty acids was done to the serum samples taken on the day of admission. We found 111 significantly (p<0.0005) altered identified metabolites between the study groups. Our main finding was that levels of glycine conjugated bile acids, glutamic acid, 7-methylguanine and several phosphatidylcholines were elevated in the progressive ALD group in comparison to both the non-progressive ALD group and the controls. Glycine conjugated bile acid, glutamic acid and 7-methylguanine also positively correlated with increased levels of aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, cell death biomarker M65, and liver stiffness. Our results indicate that the enterohepatic cycle of glycine conjugated bile acids as well as lipid and energy metabolism are altered in early forms of progressive ALD. These metabolic processes could be a target for preventing progression of ALD.
- Open Access
- 28 April 2022
- Published by Elsevier in EBioMedicine
- Vol. 80, 104033
Liver alterations are not improved by inulin supplementation in alcohol use disorder patients during alcohol withdrawal: A pilot randomized, double-blind, placebo-controlled study
- 28 April 2022
- Published by Elsevier in EBioMedicine
- Vol. 80, 104033
Open AccessLiver alterations are not improved by inulin supplementation in alcohol use disorder patients during alcohol withdrawal: A pilot randomized, double-blind, placebo-controlled study
- Open Access
- 1 May 2021
- Published by Elsevier in Clinical Nutrition
- Vol. 40 (5) , 2673-2682
Dietary fiber deficiency as a component of malnutrition associated with psychological alterations in alcohol use disorder
- 1 May 2021
- Published by Elsevier in Clinical Nutrition
- Vol. 40 (5) , 2673-2682
Open AccessDietary fiber deficiency as a component of malnutrition associated with psychological alterations in alcohol use disorder
- Open Access
- 1 May 2021
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 94, 289-298
Prebiotic effect on mood in obese patients is determined by the initial gut microbiota composition: A randomized, controlled trial
- 1 May 2021
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 94, 289-298
Open AccessPrebiotic effect on mood in obese patients is determined by the initial gut microbiota composition: A randomized, controlled trial
- Open Access
- 1 April 2021
- Published by Elsevier in Clinical Nutrition
- Vol. 40 (4) , 2035-2044
Specific gut microbial, biological, and psychiatric profiling related to binge eating disorders: A cross-sectional study in obese patients
- 1 April 2021
- Published by Elsevier in Clinical Nutrition
- Vol. 40 (4) , 2035-2044
Open AccessSpecific gut microbial, biological, and psychiatric profiling related to binge eating disorders: A cross-sectional study in obese patients
- Open Access
- 1 December 2020
- Published by Elsevier in Clinical Nutrition
- Vol. 39 (12) , 3618-3628
Link between gut microbiota and health outcomes in inulin -treated obese patients: Lessons from the Food4Gut multicenter randomized placebo-controlled trial
- 1 December 2020
- Published by Elsevier in Clinical Nutrition
- Vol. 39 (12) , 3618-3628
Open AccessLink between gut microbiota and health outcomes in inulin -treated obese patients: Lessons from the Food4Gut multicenter randomized placebo-controlled trial
- 1 May 2019
- Vol. 74, 281-286
[What is the role of the gut microbiota in the development of alcohol use disorders?]
Alcohol addiction is a complex and multifactorial disease influenced by social, psychological and biological aspects. The current pharmacological drugs used in the management of alcohol dependence have shown only a modest efficacy and the relapse rate remains high in this disease. Recently, the gut microbiota, a huge and dynamic ecosystem made up of billions of microorganisms living in our intestine, has been shown to regulate many important functions for human health. Indeed, the gut microbiota is known to influence our metabolism, our immune system as well as our nervous system with consequences for brain functions, mood and behaviour. We have shown that heavy and chronic alcohol consumption induced important changes in the composition of the gut microbiota. Furthermore, the microbial changes are associated with the severity of depression, anxiety and alcohol craving that are important factors predicting the risk of relapse. This suggests the existence of a gut-brain axis in alcohol dependence and supports the development of new therapeutic alternatives, targeting the gut microbiota, in the management of alcohol dependence.
- 1 May 2019
- Vol. 74, 281-286
[What is the role of the gut microbiota in the development of alcohol use disorders?]
Alcohol addiction is a complex and multifactorial disease influenced by social, psychological and biological aspects. The current pharmacological drugs used in the management of alcohol dependence have shown only a modest efficacy and the relapse rate remains high in this disease. Recently, the gut microbiota, a huge and dynamic ecosystem made up of billions of microorganisms living in our intestine, has been shown to regulate many important functions for human health. Indeed, the gut microbiota is known to influence our metabolism, our immune system as well as our nervous system with consequences for brain functions, mood and behaviour. We have shown that heavy and chronic alcohol consumption induced important changes in the composition of the gut microbiota. Furthermore, the microbial changes are associated with the severity of depression, anxiety and alcohol craving that are important factors predicting the risk of relapse. This suggests the existence of a gut-brain axis in alcohol dependence and supports the development of new therapeutic alternatives, targeting the gut microbiota, in the management of alcohol dependence.